Glucagon
FDA-approved drugAlso known as: Glucagonum, Glucagone, Glukagon Novo, Glucagon, pig, 76LA80IG2G, CHEBI:5391, Glucagon, porcine, for bioassay, Glukagon
Glucagon (Glucagonum, Glucagone, Glukagon Novo) is classified under other / experimental, an FDA-approved drug.
Read the full guide: what the research shows on Glucagon →What the research says
Aggregated from the cited literature below. We summarize sources — we don't author claims.
Glucagon is a pancreatic alpha-cell–secreted peptide hormone described as an essential regulator of metabolic homeostasis. Research over time has characterized glucagon’s roles in hepatic glucose homeostasis and has expanded glucagon biology to include additional hepatic regulation of lipid and other metabolic pathways. PMIDs: [37367959, 38300523]
Mechanism (as reported)
Research describes glucagon’s hepatic actions in glucose homeostasis and broader metabolic regulation within the hepatocyte, including effects related to fatty acid oxidation, endogenous lipid synthesis, hepatic amino acid metabolism, ketone body metabolism, and mitochondrial turnover/function. PMIDs: [38300523, 37367959]
Key findings (each cites a source)
- A review reported that glucagon is a peptide hormone secreted from pancreatic alpha cells and is described as an essential regulator of metabolic homeostasis. (PMID: 37367959) [PMID 37367959]
- Research described glucagon’s ability to promote hepatic glucose production as well characterized, with growing evidence suggesting glucagon is more than a glucose-mobilizing hormone. (PMIDs: 38300523, 37367959) [PMID 38300523, 37367959]
- A study reported that glucagon action in the liver includes effects consistent with increased fatty acid oxidation and attenuation of endogenous lipid synthesis. (PMID: 38300523) [PMID 38300523]
- Research reported that glucagon signaling in hepatocytes is implicated in hepatic amino acid and ketone body metabolism and in mitochondrial turnover/function. (PMID: 38300523) [PMID 38300523]
- A review reported the concept of 'glucagon resistance,' proposing that in individuals with diabetes and fatty liver diseases glucagon’s hepatic actions may be partly impaired, associated with hyperglucagonaemia and related metabolic changes. (PMID: 37367959) [PMID 37367959]
- A study discussed glucagon receptor agonism (balanced with incretin hormone receptor agonism such as GLP-1) as being developed as a therapeutic target in metabolic diseases like MASLD/MASH, and noted potential links to obesity and chronic kidney disease. (PMID: 38300523) [PMID 38300523]
- A review reported that mimicry experiments of glucagon signaling have supported development of glucagon receptor antagonists, glucagon receptor agonists, and dual/triple receptor agonists combining glucagon and incretin hormone receptor agonism. (PMID: 37367959) [PMID 37367959]
Independent test grades
No independent third-party test data is available for Glucagon yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.
Research literature (10)
Consolidated from PubMed — each links to the original record.
- Hepatic glucagon action: beyond glucose mobilization.
Kajani S, Laker RC, Ratkova E, Will S, Rhodes CJ · Physiological reviews · 2024 · PMID 38300523
- Corrination mitigates peptide aggregation as exemplified for Glucagon.
Liles A, Cham N, Opp ML, Tinsley IC, Chepurny OG, Holz GG · Peptides · 2024 · PMID 38092266
- Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors.
Vishnoi S, Bhattacharya S, Walsh EM, Okoh GI, Thompson D · Journal of chemical information and modeling · 2023 · PMID 37523325
- 100 years of glucagon and 100 more.
Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, Finan B, Gluud LL, Dean ED · Diabetologia · 2023 · PMID 37367959
- [Genetic aspects of type 1 glucagon peptide agonists clinical efficacy: A review].
Golovina EL, Grishkevich IR, Vaizova OE, Samoilova IG, Podchinenova DV, Matveeva MV · Terapevticheskii arkhiv · 2023 · PMID 37167150
- The Molecular Determinants of Glucagon-like Peptide Secretion by the Intestinal L cell.
Brubaker PL · Endocrinology · 2022 · PMID 36156130
- Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator.
Thulesen J · Current protein & peptide science · 2004 · PMID 14965320
FAQ
- What is Glucagon?
- Glucagon (Glucagonum, Glucagone, Glukagon Novo) is classified under other / experimental, an FDA-approved drug. Research goals associated with it include metabolic & weight, hormonal & endocrine.
- Is Glucagon FDA-approved?
- Yes — Glucagon is approved by the FDA (marketed as Glucagonum, Glucagone).
- What does the research on Glucagon say?
- peptideone aggregates 10 references from PubMed for Glucagon. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.